QIAGEN Launches Novel Liquid Biopsy Solutions and NGS Panels with Seamlessly Integrated Bioinformatics to
Support Advances in Cancer Research
AACR 2019 includes over 30 abstracts building on QIAGEN’s Sample to Insight solutions to advance
understanding of cancer and commitment to improve outcomes
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of new solutions designed to advance cancer
research as part of its highlights at the American Association for Cancer Research (AACR) 2019 Annual Meeting from March 29 to
April 3, 2019, in Atlanta, Georgia. More than 30 studies being presented at AACR 2019 cite molecular testing tools from
QIAGEN’s Sample to Insight portfolio.
These products involve:
- New solution bundles for all QIAseq and QIAact DNA panels for next-generation sequencing (NGS),
integrating its market-leading CLC Genomics Workbench and QIAGEN Clinical Insight-Interpret software with these assays for
seamless secondary analysis and tertiary interpretation of complex genomic data. The proprietary technology driving the superior
performance of QIAGEN’s NGS panels was described in a recent Nature article:
https://www.nature.com/articles/s41598-019-41215-z
- QIAGEN is introducing its exoRNeasy Midi and Maxi Kits for isolation of exosomes and other
extracellular vesicles from urine and other samples, as well as the miRNeasy 96 Advanced QIAcube HT Kit for automated
purification of total RNA, including miRNA, from serum and plasma samples. These are two novel liquid biopsy workflows for cancer
research designed to enable non-invasive extraction and purification of ribonucleic acid (RNA).
Please find the full press release
here
###
QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711
Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com
Public Relations
Thomas Theuringer
+49 2103 29 11826
Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190328005773/en/